K-911 Phese 3 confirmatory Study

Phase 3 confirmatory study of K-911 (bimatoprost grenod) in patients with primary open-angle glaucoma (broad definition) or ocular hypertension

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250050

Enrollment

500

Registered

2025-06-20

Start date

2025-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POAG (broad definition), OH

Interventions

K-911 ophthalmic solution 0.1% or latanoprost ophthalmic solution 0.005% administered topically

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with POAG (board definition) or OH

Exclusion criteria

Exclusion criteria: (1)Patients in whom the best-corrected visual acuity is <0.3 (2)Patients who are expected to undergo the following treatments during the study period. 1)Use of anti-glaucoma/anti-OH drugs 2)Use of contact lenses.

Design outcomes

Primary

Measure	Time frame
Efficacy:Changes from baseline in intraocular pressure at 2, 4 and 6 week (at 16:00) Safety:Presence or absence of adverse events and side effects	—

Secondary

Measure	Time frame
Efficacy Percent changes from baseline in intraocular pressure at 2, 4 and 6 week (at 16:00)	—

Contacts

Public ContactContact for clinical trial information

Kowa Company, Ltd.

ctrdinfo@kowa.co.jp+81-3-3279-7454

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026